Australian Super Pty LTD Neurocrine Biosciences Inc Transaction History

Australian Super Pty LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 21, 2023	BUY	$94.11 - $123.02 $5.88 Million - $7.68 Million	62,467 New	62,467 $6.32 Million
Q1 2022 Apr 29, 2022	SELL	$72.45 - $94.81 $5.35 Million - $7 Million	-73,792 Closed	0 $0
Q4 2021 Jan 24, 2022	SELL	$79.65 - $106.22 $4.94 Million - $6.59 Million	-62,037 Reduced 45.67%	73,792 $6.4 Million
Q3 2021 Nov 12, 2021	SELL	$86.18 - $99.03 $6.16 Million - $7.08 Million	-71,451 Reduced 34.47%	135,829 $13 Million
Q2 2021 Aug 12, 2021	BUY	$89.43 - $102.27 $2.96 Million - $3.38 Million	33,076 Added 18.99%	207,280 $20.2 Million
Q1 2021 May 14, 2021	BUY	$87.57 - $119.4 $12.2 Million - $16.7 Million	139,732 Added 405.35%	174,204 $16.9 Million
Q4 2020 Feb 11, 2021	BUY	$86.91 - $108.33 $3 Million - $3.73 Million	34,472 New	34,472 $3.3 Million

625

94.2M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Australian Super Pty LTD, based on Form 13F filings with the SEC.

Stay updated on Australian Super Pty LTD with notifications on news.